A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 29, 2019

Primary Completion Date

August 22, 2019

Study Completion Date

August 22, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

venetoclax

tablet; oral

DRUG

lenalidomide

capsule; oral

DRUG

dexamethasone

tablet; oral

Trial Locations (22)

2145

Westmead Hospital /ID# 210267, Westmead

3065

St. Vincents Hosp Melbourne /ID# 210266, Fitzroy

3084

Austin Hospital /ID# 210268, Heidelberg

3168

Monash Medical Centre /ID# 210269, Melbourne

5042

Flinders Centre for Innovation /ID# 210697, Bedford Park

15232

UPMC Hillman Cancer Ctr /ID# 208121, Pittsburgh

27710

Duke University Hospital /ID# 208306, Durham

28009

Hspital Universitario Gregorio Maranon /ID# 209926, Madrid

28021

Clinica Universitar de Navarra - Madrid /ID# 210131, Madrid

28041

Hosp Univ 12 de Octubre /ID# 209887, Madrid

31008

Clinica Universitar de Navarra - Pamplona /ID# 209883, Pamplona

46017

Hospital Univ Dr. Peset /ID# 209884, Valencia

48201

Karmanos Cancer Institute /ID# 208805, Detroit

48202

Henry Ford Hospital /ID# 208481, Detroit

90095

University of California, Los Angeles /ID# 208516, Los Angeles

91010

City of Hope /ID# 212211, Duarte

94904

Marin Cancer Care /ID# 208476, Greenbrae

T2N 4N2

Tom Baker Cancer Centre /ID# 208549, Calgary

M5G 2M9

Princess Margaret Cancer Centr /ID# 208923, Toronto

H1T 2M4

Hopital Maisonneuver-Rosemont /ID# 208550, Montreal

H3G 1A4

McGill Univ HC /ID# 208486, Montreal

08036

Hospital Clinic de Barcelona /ID# 209888, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

AbbVie

INDUSTRY